Nov 12, 2024 Press Releases
PDF Version Naples, FL – November 12, 2024 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug...
Jul 29, 2024 Press Releases
PDF Version AT-02 has been granted COMP positive opinions for orphan medicinal product designations in the EU for both ATTR and AL amyloidosis. AT-02 is the Company’s lead pan-amyloid removal therapeutic candidate in development. AT-02 is currently being evaluated in...
